Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019

Corporate 24 April 2024 7 mins read

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

Announcement 22 April 2024 5 mins read

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Announcement 02 April 2024 7 mins read

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Corporate 15 February 2024 1 mins read

Ipsen S.A. publishes its 2023 Consolidated Financial Statements

Corporate 13 February 2024 14 mins read

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  

Corporate 08 February 2024 8 mins read

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Corporate 22 January 2024 10 mins read

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024

Corporate 07 December 2023 10 mins read

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

Announcement 07 December 2023 5 mins read

Capital Markets Day 2023 – Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

Corporate 26 October 2023 7 mins read

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance